Objectives: Acetaminophen (APAP) is a mainstay for pain management worldwide. The intravenous (IV) formulation has been widely used in Europe for more than 20 years in adults and children. In the United States, IV APAP obtained full approval from the Food and Drug Administration in 2010. There is emerging literature to suggest the use of IV APAP for pain reduction in the emergency department (ED). This evidence-based review examines the evidence pertaining to the use of IV APAP for acute pain control in the ED.
tenderness and normal genitourinary examination. You performed a bedside renal ultrasound of the left kidney and noted moderate hydronephrosis supporting your clinical suspicion for nephrolithiasis. You prescribe intravenous (IV) ketorolac 30 mg and IV morphine 5 mg. You share your case with a colleague who recalls seeing a paper on the use of IV acetaminophen (APAP) for acute pain. After this encounter, you decide to review the evidence justifying the use of IV APAP as the primary analgesic for acute pain in the ED.
BACKGROUND
Acetaminophen has been a mainstay for pain management for many years. The IV formulation has been widely used in Europe for more than 20 years in adults and children. In the United States, IV APAP obtained full approval from the Food and Drug Administration in 2010. 1 The mechanism of action of APAP induced analgesia is not well understood. 1, 2 It has been postulated that the primary analgesic effect of APAP is induced by cyclooxygenase inhibition, N-methyl-D-aspartate receptor inhibition, and serotonergic antagonism in the central nervous system. [1] [2] [3] [4] Traditional formulations of APAP include oral and rectal forms. Aside from the route of drug delivery, there are other marked differences in the pharmacokinetic properties of the IV formulation.
1-3 IV APAP results in a rapid elevation in plasma concentration. 2, 3 Compared to the oral formulation, the time to reach maximum concentration for IV APAP (15 minutes) is more predictable than the oral immediate-release (10-60 minutes), oral extended-release (60-120 minutes), and rectal (variable) formulations. 1, 5 APAP is primarily metabolized in the liver and less than 5% of free drug is excreted in the urine. 5 Since first-pass metabolism is bypassed with the IV route, initial drug exposure to the liver is reduced by nearly twofold compared with the oral formulation.
2 IV APAP's role as an adjunctive analgesic has been well documented in the postoperative setting. 5, 6 In the ED, the use of IV APAP for acute pain is not a common practice. Its use is often a topic of controversy due its acquisition cost and perceived effectiveness for various types of acute pain. However, recent evidence has emerged that suggests the use of IV APAP as the primary analgesic for acute pain control in the ED. The objective of this review is to answer the following research question: "In ED patients with moderate to severe pain, is the administration of IV APAP as the primary analgesic, compared to placebo or comparator analgesics, safe and effective in pain control?"
CRITERIA FOR CONSIDERING STUDIES FOR THE REVIEW

Target Study Design
Randomized controlled trials (RCTs) that described the use of IV APAP as the primary analgesic in the ED were selected for the review.
Participants
Eligible participants included patients of any age range who presented to the ED for acute pain and received at least one dose of IV APAP in the ED. Patients who received IV APAP in a setting outside the ED or for indications other than analgesia were excluded.
Intervention
The intervention consisted of the administration of IV APAP. No restrictions were set for the route of administration for the comparator groups.
Comparison
The comparison consisted of the administration of placebo or active comparator (analgesic pain medications).
Outcomes
The primary outcome of interest in this review was the difference in pain scores from baseline to the cutoff time specified in the original trial between IV APAP and active comparator or placebo. Secondary outcomes included the incidence of adverse events and reduction in the amount of adjuvant analgesics consumed by patients who received IV APAP.
SEARCH METHODS
This evidence-based review was structured according to the PRISMA statement. 7 A methodologic protocol was established a priori by the study investigators (BS, MW) and adhered throughout. A search of the MEDLINE database from July 1970 to July 2015 and EMBASE from July 1970 to July 2015 was conducted. The search strategies are presented in Data Supplement S1 (available as supporting information in the online version of this paper). Additional references were identified from a review of literature citations. Abstracts were screened for relevance and subsequent publications relating to the use of IV APAP as an analgesic for acute pain in the ED were identified. Only English-published literature that evaluated the use of IV APAP as the primary analgesic for acute pain control in humans was included. Duplicate articles, unpublished reports, abstracts, and review articles were not considered. Two authors (BS, MW) independently screened all titles, abstracts, and full-text articles. Articles were eliminated according to the inclusion and exclusion criteria. Any disagreement was resolved by a third author (SM). The PRISMA checklist and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria were utilized to guide the structure and reporting of the identified literature. 7, 8 The primary search identified a total of 1,360 publications. The number of citations was reduced, according to their relevance for this review (Figure 1 ). The search identified 14 RCTs, which fulfilled our criteria. We performed our review based on these 14 publications. Data extraction was performed independently by two authors (BS, MW) via a standardized electronic data extraction form.
Description of Included Trials
Of the 14 randomized controlled trials that met the inclusion criteria, 12 were double-blinded, and two were nonblinded. All 14 trials used validated pain scales to measure analgesic efficiency and incidence of adverse events as a measure of safety. In the literature identified, IV APAP was utilized as the primary analgesic for acute pain control due to renal colic, abdomen, lower back, headache, bone fracture, acute trauma, or scorpion sting. All patients within the randomized trials received a one-time dose of IV APAP at 1 gram per dose. Four randomized trials infused IV APAP at a rate faster than 15 minutes. [9] [10] [11] [12] Turkcuer et al. 13 described administering IV APAP as "a rapid infusion." The characteristics of studies included in this review are summarized in Table 1 .
Quality Assessment of the Included Studies
An assessment of factors (randomization concealment, patient selection, adequacy of blinding, and duration of follow-up) that may contribute to risk of bias was conducted independently by three reviewers (BS, MW, TT) based on the PRISMA statement. In the case of discrepancy, a fourth reviewer (SM) was consulted. An evaluation on the methodologic quality of the evidence based on the GRADE criteria was conducted independently by two reviewers (BS, MW). 8 In the case of disagreement, a third reviewer (SM) was consulted. An assessment of the risk of bias and level of methodologic quality for the identified literature is summarized in Table 2 .
RESULTS
A summary of the primary outcome from the included literature is presented in Table 3 . The data collected from a total of 1,472 patients revealed conflicting results and conclusions.
A significant reduction in pain scores with IV APAP was found in three of the 14 trials. 9, 10, 14 Of the three trials, two compared IV APAP to IV morphine. 9, 10 In the third trial, Grissa et al., 14 reported of a greater reduction in pain scores when IV APAP was compared with piroxicam. A total of eight randomized trials 12, 13, [15] [16] [17] [18] [19] [20] reported no detectable differences in the observed pain scores between IV APAP and comparator groups. Oguzturk et al., 12 Azizkhani et al., 21 and Aksel et al. 22 reported of improved analgesia with morphine, tramadol, and topical lidocaine, respectively. A summary of the incidence of adverse events in patients who received IV APAP is presented in Table 4 . Two trials detected a significant difference in the incidence of reported adverse events. 15, 21 In the first trial, Zare et al. 15 18 also reported a significant difference in the total number of patients who experienced an adverse event, favoring IV APAP versus IV morphine (7.2% vs. 29.6%, p = 0.03). However, description on the type of adverse events was not presented. Of interest, Masoumi et al. 9 reported three cases of "restlessness" in patients who received IV APAP. No further description of the adverse event was provided by the original reference. However, it was reported that the events resolved when the infusion rate was slowed.
A detailed summary of rescue protocols described in the identified literature is presented in Table 5 . The use of rescue analgesia was described in 10 randomized trials. 9, 10, [13] [14] [15] [16] [17] [18] [19] 22 In four trials, the number of patients who required rescue analgesia in the IV APAP group was fewer than those who received active comparators. 9, 14, 17, 19 Of these trials, only Masoumi et al. 9 detected a significant decrease in the number of patients who required rescue opioids, favoring IV APAP. In this trial, 17/54 (31%) patients in the APAP group versus 30/ 54 (55%) patients in the morphine group required rescue analgesia (p = 0.01).
Quality of Trials
The trials identified in this review had a small sample size or various methodologic flaws. [9] [10] [11] [13] [14] [15] [16] [17] 21 Information on the procedure for blinding the data collector or data assessor were not presented. [9] [10] [11] [13] [14] [15] [16] [17] 21 Randomization concealment was not reported in five trials. 10, 12, 18, 20, 21 A detailed description of reported adverse events was not available. 16, 17 Data on the power and sample size to detect significant differences for the primary outcome were not presented in three trials. 10, 21, 22 Protocols for the use of rescue analgesia were not mentioned in five trials. 10, 12, 13, 20, 21 In the trials which described the use of rescue analgesia, data on the agents 15, 18, 19 or doses 9, 11, [14] [15] [16] [17] [18] [19] 22 consumed were not presented. Two trials provided unclear descriptions of the protocols used for providing rescue analgesia. 14, 18 Grissa et al. 14 and Craig et al. 18 described rescue therapy as "the need of intravenous morphine titration" and "intravenous morphine titrated to effect," respectively. Both trials did not provide data on the frequency of medication administration or the total doses that were administered and consumed. Thus, we were unable to evaluate the potential impact that rescue analgesia had on the reported primary outcomes. CIs that would provide information about point estimates or the degree of uncertainty for the reported pain scores 9, 10, [12] [13] [14] [15] [17] [18] [19] [20] 22 or adverse events 9-11,14,18 were not consistently presented. Incomplete presentation of data was also observed. One trial reported of significant differences in the overall incidence of adverse events between the intervention and comparator group without providing descriptions of the specific adverse events that were observed. 18 Due to various methodologic flaws, the level of evidence assigned to the individual trials ranged from very low to moderate. Primary: 100-mm VAS change at designated intervals after medication administration Secondary: adverse events APAP = acetaminophen; GCS = Glascow Coma Scale; ICHD = international classification of headache disorders; IM = intramuscular; IV = intravenous; LBP = lower back pain; NRS = numeric rating scale; NSAID = nonsteroidal anti-inflammatory drugs; P/E = physical examination; VAS = visual analog scale; VRS = verbal rating scale. *Time of infusion not provided by study investigators.
DISCUSSION
Returning to the clinical scenario, this review provides some guidance on the use of IV APAP in the ED. The data revealed in this review provided limited evidence to support the use of IV APAP as the primary analgesic for acute pain. Of the 14 trials included in this review, three trials reported of significant reduction in pain scores. 9, 10, 14 In these trials, the indications for IV APAP included acute renal colic 9,14 and headache. 10 We also noted that eight randomized trials compared IV APAP with IV morphine. [9] [10] [11] 15, [17] [18] [19] 21 Interestingly, these trials yielded conflicting results regarding the primary outcome. Potential explanations for the observed results reported in these trials may include underdosing of morphine or a lack of repeated dosing, titrated to effect. The most frequently reported adverse events in the identified literature were nausea, vomiting, and itchiness. Of interest, no adverse events were reported for the three randomized trials, which infused IV APAP at a rate faster than 15 minutes. 9, 10, 12 In the identified trials that presented data on the use of rescue analgesia, four trials reported a lower number of patients requiring rescue analgesia in the IV APAP group versus active comparators. 9, 11, 17, 19 Of interest, Masoumi et al. 9 were the only investigators to detect a significant difference in the number of patients who required rescue analgesia, favoring IV APAP. In two other trials, 16, 17 patients in the IV APAP group had a higher rate of rescue analgesia requirement (not statistically significant). None of the identified randomized trials presented data on the amount of opioids consumed by patients who requested rescue analgesia.
IV APAP may be considered in scenarios where an analgesic with a fast onset of action is required. It may also be considered when the use of alternate analgesics is not indicated due to contraindications, drug-drug interactions or potential worsening of patient outcomes. There are several important factors to consider when initiating IV APAP in the ED. Prior to order entry, physicians need to determine if IV APAP is on the hospital's formulary of drugs. Policymakers need to consider the acquisition cost of the drug when considering the drug for routine use in the ED. None of the identified trials included in this review conducted cost-effective analyses. It may be necessary to retrieve IV APAP N/A = information not available from original study; RCT = randomized controlled trial. *Level of evidence was determined using Grading of Recommendations Assessment, Development, and Evaluation (GRADE system). †Two individual nurses who prepared and administered medications were blinded. It was not known if the attending physician (s) who evaluated patients for eligibility was/were blinded. ‡Minimal number of patients per group needed to detect significant difference not reported but significant differences claimed by original reference. §The specific dose utilized was not reported by the original reference. Applying the Evidence Emergency physicians currently have numerous options available to them for managing pain in the ED. When parenteral administration of pain medication is preferred or indicated, IV opioids (e.g., morphine) and nonsteroidal anti-inflammatory drugs (e.g., ketorolac) are widely available and safe to use in most ED patients. In the rare instances when such medications are contraindicated or not available, IV APAP should be considered. However, the existing evidence does not support or refute its use as an effective pain control remedy in the ED setting. Nonetheless, this review showed that the incidence of adverse events seems to be limited and additional medical intervention is not required. For future implications, this review highlighted the need for well-designed clinical studies to further confirm the potential applicability and benefits of IV APAP. Future research could also shed light on whether the use of IV APAP can decrease opioid consumption in the ED and whether it can affect care process outcomes such as patient satisfaction, ED length of stay, or healthcare costs. †Data reported as median (interquartile range) from original reference. 
LIMITATIONS
This review lacked the qualities of a rigorous systematic review or meta-analysis. Non-English language literature was not evaluated. None of the included trials were conducted in the United States. Therefore, the findings might not be generalizable to U.S. EDs. The quality of the review's findings was affected by the quality of the original articles. Due to significant heterogeneity in methodology and outcomes assessment, pooling the data and reporting summary results was not possible.
CONCLUSIONS
This review consisted of 14 randomized clinical trials enrolling a total of 1,472 patients. The data revealed in this review provided conflicting conclusions and limited evidence to support the use of IV acetaminophen as the primary analgesic for acute pain.
